Van Wagener Brian
Known title: Chief Financial OfficerCIK: 0002032608
Associated companies
Transaction History
| VEEV | ▲ Buy | Option Exercise | 1,636 | $0 | 10/1/2026 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 705 | $199K | 10/1/2026 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 1,635 | $0 | 7/1/2026 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 693 | $128K | 7/1/2026 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 872 | $0 | 4/1/2026 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 370 | $64K | 4/1/2026 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 871 | $0 | 1/1/2026 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 321 | $72K | 1/1/2026 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 872 | $0 | 10/1/2025 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 274 | $80K | 10/1/2025 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 872 | $0 | 7/1/2025 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 274 | $78K | 7/1/2025 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 258 | $59K | 4/1/2025 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 823 | $0 | 4/1/2025 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 1,370 | $0 | 1/1/2025 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 477 | $100K | 1/1/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Veeva Gains Investor Attention Amid R&D Growth and AI Focus
Veeva Systems is drawing investor interest as analysts note strong R&D growth and a positive outlook. The company has secured a major research partner that now uses its software as the default clinical platform, and a recent IQVIA deal expands its market reach. Large institutional investors are also increasing exposure to Veeva as part of an AI software play.
Veeva Gains Investor Attention Amid R&D Growth and AI Focus. Veeva Systems is drawing investor interest as analysts note strong R&D growth and a positive outlook. The company has secured a major research partner that now uses its software as the default clinical platform, and a recent IQVIA deal expands its market reach. Large institutional investors are also increasing exposure to Veeva as part of an AI software play.